Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 10/20 | 0.38 |
| ▸ | HTR1B | P28222 | 7/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6890795 | 1.00 | DRD2 (0.41) | DRD2SLC6A4ADRA1DCTSSHTR1D | |
| Hydrochloric Acid SCHEMBL6897558 | 0.79 | DRD2 (0.58) | DRD2CHRM2 | |
| SCHEMBL1673484 | 0.70 | MEN1 (0.51) | — | |
| Bromide SCHEMBL7864959 | 0.69 | DRD2 (0.47) | DRD2SLC6A4CTSSHTR1DHTR1B | |
| SCHEMBL694609 | 0.68 | AVPR2 (0.40) | DRD2SLC6A4CTSS | |
| SCHEMBL6896988 | 0.67 | MAPT (0.42) | DRD2SLC6A4ADRA1DCTSS | |
| SCHEMBL8810281 | 0.67 | DYRK1A (0.41) | DRD2SLC6A4ADRA1DCTSSHTR1D | |
| SCHEMBL16986213 | 0.67 | ALDH1A1 (0.52) | SLC6A4 | |
| SCHEMBL16986211 | 0.67 | ALDH1A1 (0.52) | SLC6A4 | |
| SCHEMBL6975606 | 0.67 | HTR1A (0.38) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806275-B2 | PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6407121-B1 | DOPAMINE D4 RECEPTOR ANTAGONISTS; PSYCHOLOGICAL AND BRAIN DISORDERS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | NIHON NOHYAKU CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1070715-A1 | ARYLPIPERIDINE DERIVATIVES AND USE THEREOF | Nihon Nohyaku Co., Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156283-A1 | Arylpiperidine derivatives and use thereof | DRD1, DRD4, DRD2 | DRD2 3/4885SLC6A4 18/4885ADRA1D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.